Skip to main content

Table 6 The main studies describing the effectiveness/limitations of the HA 330 cartridge

From: Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls

 

Huang et al. 2010 [56]

Huang et al. 2013 [57]

Study design

RCT

RCT

Study population (n)

44 sepsis or septic shock patients

46 ALI/extra-pulmonary sepsis patients

EAA assessment

–

–

Prescribed dose

HP for 2 h for 3 days

HP for 2 h for 3 days

Survival

• ICU mortality 12.5% in HA vs 45.0% in the controls (p = 0.02)

• Hospital mortality 37.5% in HA vs 50.0% in the controls (p = 0.81)

• 28-day mortality 45.8% in HA vs 55.0% in controls (p = 0.47)

• ICU mortality 24% in HA vs 57.14% in the controls (p = 0.02)

• 28-day mortality 28% in HA vs 66.7% in the controls (p = 0.009)

Length of ICU stay (days)

12.4 ± 3.1 in HA vs 19.5 ± 4.0 in controls (p = 0.03)

15.5 ± 4.0 in HA vs 19.4 ±  3.1 in controls (p = 0.04)

Hemodynamics

Significant reduction in VP dose in the HA group vs increase in the control group (p = 0.01)

Significant reduction in VP dose in the HA group vs increase in the control group (p = 0.032)

Other results

Significant difference in IL-8 and IL-6 levels between the two groups at day 3 (p = 0.03 and 0.01, respectively)

Significant difference in IL-1 and TNF-a in BAL fluid between the two groups (p = 0.02 and 0.04, respectively)

Safety

• 1 patient with fever in the HA group

• Transient reduction in platelet counts in the HP group

–

  1. RCT randomized controlled trial, ALI acute lung injury, EAA endotoxin activity assay, HA hemadsorption, HP hemoperfusion, ICU intensive care unit, TNF tumor necrosis factor, BAL broncho-alveolar lavage, VP vasopressor, IL interleukin